{"id":7727,"date":"2025-08-14T14:56:46","date_gmt":"2025-08-14T14:56:46","guid":{"rendered":"https:\/\/stoxpo.com\/?p=7727"},"modified":"2025-08-14T14:56:46","modified_gmt":"2025-08-14T14:56:46","slug":"eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2025\/08\/14\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\/","title":{"rendered":"Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Partnership leverages artificial intelligence to accelerate discovery of next-generation treatments for obesity and cardiometabolic diseases<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Eli Lilly (LLY) has entered into a landmark agreement with Superluminal Medicines, a privately held biotech firm, to harness artificial intelligence in the race to develop innovative obesity drugs. The deal, announced Thursday, is valued at up to $1.3 billion and grants Lilly access to Superluminal\u2019s proprietary AI-driven drug discovery platform.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The collaboration aims to accelerate the identification and development of potential drug candidates targeting cardiometabolic diseases and obesity, a market projected to reach $150 billion within the next decade. Under the terms, Lilly will hold exclusive rights to develop and commercialize any drug candidates discovered through the partnership. Superluminal stands to receive upfront and milestone payments, an equity investment, and tiered royalties on net sales.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Superluminal\u2019s leading program focuses on the melanocortin 4 receptor, a protein linked to rare genetic forms of obesity. This candidate is slated to begin human trials next year, signaling a strategic move toward both rare and more widespread obesity treatments.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Lilly has been aggressively expanding its obesity portfolio, including a 2023 partnership with Hong Kong-listed Laekna to develop an experimental therapy designed to help patients lose weight while maintaining muscle mass. This latest alliance underscores the company\u2019s commitment to next-generation drug innovation through both in-house research and strategic collaborations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For Superluminal, the deal represents a major validation of its AI-enabled approach, which promises to speed up the traditionally lengthy drug discovery process. By combining Lilly\u2019s clinical and commercial expertise with advanced computational tools, the partnership aims to address one of the world\u2019s fastest-growing health challenges with greater speed and precision.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">If successful, the collaboration could yield breakthrough therapies that reshape obesity treatment and strengthen Lilly\u2019s position as a global leader in the field.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2025\/08\/14\/ulta-and-target-to-end-mini-store-partnership-in-2026\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Ulta and Target to End Mini-Store Partnership in 2026<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Partnership leverages artificial intelligence to accelerate discovery of next-generation treatments for obesity and cardiometabolic diseases Eli Lilly (LLY) has entered into a landmark agreement with Superluminal Medicines, a privately held biotech firm, to harness artificial intelligence in the race to develop innovative obesity drugs. The deal, announced Thursday, is valued at up to $1.3 billion [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1429,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"0","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"0","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]},"footnotes":""},"categories":[309],"tags":[421,544,416,418,417],"coauthors":[454],"class_list":["post-7727","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceuticals","tag-growth","tag-lly","tag-movers","tag-news","tag-stock-market"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2025\/08\/14\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Partnership leverages artificial intelligence to accelerate discovery of next-generation treatments for obesity and cardiometabolic diseases Eli Lilly (LLY) has entered into a landmark agreement with Superluminal Medicines, a privately held biotech firm, to harness artificial intelligence in the race to develop innovative obesity drugs. The deal, announced Thursday, is valued at up to $1.3 billion [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2025\/08\/14\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-14T14:56:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-chokniti-khongchum-2280571-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1709\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Luca Blaumann\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luca Blaumann\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/14\\\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/14\\\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\\\/\"},\"author\":{\"name\":\"Luca Blaumann\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\"},\"headline\":\"Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development\",\"datePublished\":\"2025-08-14T14:56:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/14\\\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\\\/\"},\"wordCount\":323,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/14\\\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-chokniti-khongchum-2280571-scaled.jpg\",\"keywords\":[\"Growth\",\"LLY\",\"Movers\",\"News\",\"Stock Market\"],\"articleSection\":[\"Pharmaceuticals\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/14\\\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/14\\\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\\\/\",\"name\":\"Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/14\\\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/14\\\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-chokniti-khongchum-2280571-scaled.jpg\",\"datePublished\":\"2025-08-14T14:56:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/14\\\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/14\\\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/14\\\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-chokniti-khongchum-2280571-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-chokniti-khongchum-2280571-scaled.jpg\",\"width\":2560,\"height\":1709,\"caption\":\"chemistry-2\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/08\\\/14\\\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\",\"name\":\"Luca Blaumann\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"caption\":\"Luca Blaumann\"},\"description\":\"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/luca-blaumann\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2025\/08\/14\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\/","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development - Stoxpo","og_description":"Partnership leverages artificial intelligence to accelerate discovery of next-generation treatments for obesity and cardiometabolic diseases Eli Lilly (LLY) has entered into a landmark agreement with Superluminal Medicines, a privately held biotech firm, to harness artificial intelligence in the race to develop innovative obesity drugs. The deal, announced Thursday, is valued at up to $1.3 billion [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2025\/08\/14\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\/","og_site_name":"Stoxpo","article_published_time":"2025-08-14T14:56:46+00:00","og_image":[{"width":2560,"height":1709,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-chokniti-khongchum-2280571-scaled.jpg","type":"image\/jpeg"}],"author":"Luca Blaumann","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Luca Blaumann","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/14\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/14\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\/"},"author":{"name":"Luca Blaumann","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806"},"headline":"Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development","datePublished":"2025-08-14T14:56:46+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/14\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\/"},"wordCount":323,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/14\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-chokniti-khongchum-2280571-scaled.jpg","keywords":["Growth","LLY","Movers","News","Stock Market"],"articleSection":["Pharmaceuticals"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/14\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\/","url":"https:\/\/stoxpo.com\/index.php\/2025\/08\/14\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\/","name":"Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/14\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/14\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-chokniti-khongchum-2280571-scaled.jpg","datePublished":"2025-08-14T14:56:46+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/14\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2025\/08\/14\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/14\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-chokniti-khongchum-2280571-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-chokniti-khongchum-2280571-scaled.jpg","width":2560,"height":1709,"caption":"chemistry-2"},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2025\/08\/14\/eli-lilly-strikes-1-3-billion-deal-with-superluminal-medicines-to-advance-ai-driven-obesity-drug-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806","name":"Luca Blaumann","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b","url":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","caption":"Luca Blaumann"},"description":"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/luca-blaumann\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=7727"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7727\/revisions"}],"predecessor-version":[{"id":7728,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7727\/revisions\/7728"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1429"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=7727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=7727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=7727"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=7727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}